Producer
Sanofi
Third of the global insulin oligopoly. Markets Lantus (glargine) — historically the world's best-selling insulin — and Toujeo. Uses E. coli fermentation at Frankfurt plant. WHO-prequalified for insulin glargine. Divesting insulin business in some regions as GLP-1 market grows.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input Sanofi supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Sanofi makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Dupixent (Dupilumab — Fastest-Growing Drug in History)
35%Vaccines (Sanofi Pasteur)
25%Insulin (Lantus/Toujeo) + Rare Disease
25%Multiple Sclerosis + Immunology
15%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Dupixent (dupilumab) — Sanofi's fastest-growing product and the fastest drug in history to reach EUR 13 billion in annual revenue — blocks IL-4 and IL-13 signaling, which are cytokines central to Type 2 (eosinophilic/allergic) inflammatory responses. The same antibody from the same Sanofi-Regeneron manufacturing is FDA/EMA-approved for: (1) Atopic dermatitis (eczema) — the skin inflammation; (2) Moderate-to-severe asthma with eosinophilic or type 2 inflammation — the lung inflammation; (3) Chronic rhinosinusitis with nasal polyps — the sinus/nasal passage inflammation; (4) Eosinophilic esophagitis — the esophageal inflammation; (5) Prurigo nodularis — the skin nodule condition; (6) COPD with type 2 inflammation — the chronic lung obstruction. All six approved conditions share the same underlying IL-4/13 biological pathway — the same immune signal that causes eczema in your skin is causing asthma in your lungs and polyps in your sinuses. Dupixent is a perfect case of a targeted biologic that works across seemingly unrelated diseases because they share a single molecular mechanism. A single antibody serves dermatology, pulmonology, otolaryngology, gastroenterology, and emerging COPD management simultaneously.
Sanofi/Regeneron ↗Origin2023
Sanofi S.A. is the product of one of the most complex pharmaceutical M&A sequences in French corporate history. The current Sanofi traces through: Sanofi SA (French petroleum company Elf Aquitaine's pharmaceutical division); Sanofi-Synthelabo (1999 merger of Sanofi with Synthelabo, itself from L'Oreal's pharma); then the 2004 hostile acquisition of Aventis for EUR 54.5 billion — the largest hostile takeover in French corporate history. Aventis itself was formed in 1999 from the merger of Hoechst AG (German chemicals/pharma, maker of aspirin-competing salicylate drugs) and Rhône-Poulenc (French chemicals/pharma). Rhône-Poulenc had itself acquired Rorer Group, Fisons, and other companies. The combined Sanofi contains heritage from: French petroleum chemicals, German synthetic dye chemistry, French industrial chemistry, and multiple US pharmaceutical acquisitions. Sanofi operates as the inheritor of a century of French and German industrial chemistry — including the same Hoechst lineage that in WWI produced chemical warfare agents. A French oil company's pharmaceutical division eventually became one of the world's largest pharmaceutical companies through European consolidation.
Sanofi S.A. ↗